The 17th Annual                                                                                 Scientific Meeting & Educa...
CME Verification Form. Upon request, a record of attendance(certificate) will be provided on-site to other health care    ...
Biological Therapies and Stem Cells                   Educational Day                       Session Chairs: Balveen Kaur, ...
Quality of Life/Symptom Management                                                                             Official Op...
Morning Plenary Session                                               Noon- 1:00 pm 	 Boxed Lunches in the Foyer          ...
1:15 pm	 CB-38	 Unexpected nuclear sublocalization of the 		       4:15 pm	 NC-07	 Long-term survivorship in primary		    ...
Morning Plenary Session        Saturday, November 17, 2012                                                                ...
11:15 am RT-09	 To compare the treatment outcomes of two 		          2:45 pm	 CB-53	 An in vivo loss of function screen fo...
3:45 pm	 CB-16	 Stress-regulated expression of miR-451 controls 			              proliferation/migration dichotomy of     ...
7:00-8:00 am	 SNO Highlights Session                                 10:30 am IT-20	 Dendritic Cell Vaccines Targeting Hum...
Society for Neuro-Oncology4617 Birch Street, Bellaire, TX 77401-5509 Tel: 713-349-0952 E-Fax: 832-201-8129         www.soc...
17th Annual Scientific Meeting & Education Day of the Society for Neuro-Oncology
Upcoming SlideShare
Loading in …5

17th Annual Scientific Meeting & Education Day of the Society for Neuro-Oncology


Published on

  • Be the first to comment

  • Be the first to like this

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide

17th Annual Scientific Meeting & Education Day of the Society for Neuro-Oncology

  1. 1. The 17th Annual Scientific Meeting & Education Day of the Society for Neuro-Oncology November 15-18, 2012 Hilton Hotel, Washington DC Meeting OverviewThe 2012 Annual Scientific Meeting and Education Day of the Societyfor Neuro-Oncology will be held at the Hilton Hotel in Washington, DC, Target Audiencefrom November 15 through November 18, 2012. In addition to a stimu- This conference should be of value to neuro-oncologists, medical oncol-lating Education Day and the abstract driven scientific sessions of the ogists, neurosurgeons, pediatric neuro-oncologists, neuroradiologists,main meeting, SNO is pleased to offer a number of exciting new fea- neuropathologists, radiation oncologists, neuropsychologists, epidemi-tures for this year’s meeting, including a special biomarkers course, a ologists, nurses, psychologists, basic and translational scientists.keynote address from Dr. Bert Vogelstein, a new Public Service Award,the inaugural Abhijit Guha Award and Lecture, expanded sessionsfor Young Investigators and an evening satellite on 1p/19q codeleted Educational Methods anaplastic gliomas. Lectures, Question-and-Answer Sessions, Panel Discussions, Posters, Other.The meeting is designed for neurosurgeons, neuro-oncologists,medical oncologists, neuropathologists, radiation oncologists, Evaluationneuroradiologists, pediatricians, laboratory scientists, nurses andother specialists involved in the research, diagnosis, care and treatment A course evaluation form will provide participants with the opportunityof central nervous system tumors. to comment on the value of the program content to their practice decisions, performance improvement activities, or possible impact on Educational Objectives patient health status. Participants will also have the opportunity to comment on any perceived commercial bias in the presentations asAfter attending the conference, participants should be able to: well as to identify future educational topics.• Construct a list of current studies on epidemiologic factors Accreditation/Credit Designation associated with central nervous system tumors (knowledge); This activity has been planned and implemented in accordance with the• Using neurocognitive intervention strategies, create a plan to Essential Areas and Policies of the Accreditation Council for Continuing diminish the impact of brain tumors and their treatments on Medical Education through the joint sponsorship of The University of patients and quality of life (knowledge, competence, performance, Texas MD Anderson Cancer Center and the Society for Neuro-Oncology. patient outcomes); The University of Texas MD Anderson Cancer Center is accredited by the ACCME to provide continuing medical education for physicians.• Discuss new research on cell biology, tumor microenvironment, signal transduction, genomic, epigenomic, proteomic and The University of Texas MD Anderson Cancer Center designates this metabolic complexity, and factors associated with angiogenesis live activity for a maximum of 27.75 AMA PRA Category 1 Credits™. and invasion in brain tumors (knowledge); Physicians should claim only credit commensurate with the extent of their participation in the activity.• Apply therapeutic strategies related to new research on genes that are associated with brain tumors (knowledge, competence, The presentations included in the Quality of Life Interventions section performance); have been designated by The University of Texas MD Anderson Cancer Center for 3.75 AMA PRA Category 1 CreditsTM in medical ethics and/• Discuss new research on CNS antitumor immunoreactivity or professional responsibility. (knowledge);• Apply advances in imaging and neuropathology to diagnose and measure response to therapy for patients with CNS tumors (knowledge, competence, performance);• Use advances in pharmacology, experimental therapeutics, biologic therapies, and radiobiology to improve future therapies for patients with CNS tumors (knowledge, competence, performance); CME Certificates and• Utilize results of new clinical studies for central nervous system Attendance Verification Certificates tumors for improved patient outcomes (knowledge, competence, performance, patient outcomes); Certificates awarding AMA PRA Category 1 CreditsTM or certificates documenting attendance will be distributed to participants when an• Utilize symptom management initiatives to improve quality of life individual departs the conference. To obtain a CME certificate, for brain tumor patients (knowledge, competence, performance). physicians must submit a completed evaluation questionnaire and a
  2. 2. CME Verification Form. Upon request, a record of attendance(certificate) will be provided on-site to other health care Program Committeeprofessionals for requesting credits in accordance with state nursingboards, specialty societies, or other professional associations. Scientific Chair E. Antonio Chiocca, MD, PhDThe University of Texas MD Anderson Cancer Center has implement-ed a process whereby everyone who is in a position to control the Education Day Chairscontent of an educational activity must disclose all relevant financial Balveen Kaur, PhDrelationships with any commercial interest that could potentially Vinay Puduvalli, MDaffect the information presented. MD Anderson also requires thatall faculty disclose any unlabeled use or investigational use (not yet Quality of Life Chairapproved for any purpose) of pharmaceutical and medical device Michael J. Glantz, MDproducts. Specific disclosure will be made to the participants prior tothe educational activity. Scientific Committee Ken Aldape, MDAgendas are subject to change because we are always striving to Manish Aghi, MD,improve the quality of your educational experience. MD Anderson may Tracy Batchelor, MD,substitute faculty with comparable expertise on rare occasions Etty (Tika) Benveniste, PhDnecessitated by illness, scheduling conflicts, and so forth. Michael Berens, PhD Markus Bredel, PhD Registration Information Jeffrey Bruce, MD Daniel Cahill, MD, PhDThe early-bird deadline for advance registration is October 15, 2012. Arnab Chakravarti, MDThere are three ways to register: Charles Eberhart, MD, PhD On-Line at: Peter Forsyth, MD Maryam Fouladi, MD Juan Fueyo, MD Mail to: Evanthia Galanis, MD SNO David Gutmann, MD PO Box 273296 Eric Holland, MD, PhD Houston, TX 77277 Mark Johnson, MD, PhD Balveen Kaur, PhD Fax to: (713) 583-1345 Maciej (Matt) Lesniak, MDThe following forms of payment are accepted: Min Li, PhD• Checks or money orders made payable to SNO Linda Liau, PhD• Credit Card Russell Lonser, MD (MasterCard, VISA, Discover, Diners Club and American Express) Elizabeth Maher, MD, PhD• Cash on-site ($50 surcharge applies if not pre-registered) Andrew Parsa, MD, PhD Scott Plotkin, MD, PhDThe registration fee for the Education Day (November 15) includes all Vinay Puduvalli, MDcourse materials, a continental breakfast and a box lunch. The registra- Jeremy Rich, MDtion fee for the Scientific Meeting (November 16-18) includes all course John Sampson, MD, PhDmaterials, daily continental breakfasts, box lunches, receptions, and Mariano Viapiano, PhDthe conference banquet. SNO will provide a receipt and confirmation of Michael Vogelbaum, MD, PhDyour registration. William Weiss, MD, PhD Gelareh Zadeh, MDSpecial Assistance: Contact SNO at (713) 349-0952 if you have anyspecial dietary or ADA accommodation needs. Hotel Information Refunds/CancellationsThe registration fee, minus a $50 administrative handling fee, is refund-able if a written or email request is received on or before November1, 2012. No refunds will be given after this date. The request for aregistration refund must include the tax identification number of thecompany or institution if the registration was paid by a company or aninstitution check. Although no refunds will be granted after November Located in the heart of Washington DC, the Washington Hilton hotel1, 2012, registration may be transferred to a colleague. is situated in the capital’s most sought after neighborhoods. Enjoy the best entertainment and nightlife Washington has to offer at the nearbyIn case of meeting cancellation, liability of the Society for Neuro- Adams Morgan, Woodley Park and the U Street Corridor. This Wash-Oncology is limited to a refund of the registration fee. The Society for ington hotel is one mile from the Smithsonian National Zoo and onlyNeuro-Oncology reserves the right to limit the number of participants four blocks from Dupont Circle Metro. Easy access to iconic Washingtonat the meeting and will not be responsible for expenses incurred by an attractions including the White House, the National Monument and theindividual whose registration is not confirmed and for whom space is Lincoln Memorial. To book your room at the reduced conference ratenot available. of $189.00, visit
  3. 3. Biological Therapies and Stem Cells Educational Day Session Chairs: Balveen Kaur, Maciej Lesniak Thursday, November 15, 2012 1:00-1:20 pm Oncolytic Viruses Juan Fueyo7:00-9:00 am Breakfast in the Foyer 1:20-1:40 pm Peptide Therapy Wadih ArapTargeted Therapies Against Primary 1:40-2:00 pm Targeting the Tumor Stem Cell: Rationale andBrain Tumors Education Day Session Clinical RelevanceCo-Chairs: Vinay Puduvalli, Balveen Kaur Jeremy Rich8:00-8:15 am Education Day: Introduction and Welcome 2:00-2:20 pm Stem Cell-Mediated Cancer Therapy – Vinay Puduvalli, Balveen Kaur First in Human Clinical Trial for Glioma Karen AboodySignal Transduction AgentsSession Chairs: Vinay Puduvalli, Frank Furnari 2:20-2.35 pm Q&A 2:35-2.50 pm Interactive Audience Quiz Session8:15-8:35 am Growth Factor Inhibitors: Rationale, Clinical Experience and Challenges Ingo Mellinghoff 3:00-3:15 pm Break8:35-8:55 am Angiogenesis Therapies: Bevacizumab and SNO Course on the Basics of Beyond Biomarkers 2012 Timothy Cloughesy Supported by the National Brain Tumor Society Course Directors: Susan Chang, Kenneth Aldape8:55-9:15 am Targeting the PI3K/AKT/mTOR Axis 3:00-3:20 pm Overview of Biomarkers W. K. Alfred Yung Martin Van den Bent9:15-9:35 am Novel Molecular Targets for Therapy of 3:20-3:40 pm Imaging Biomarkers Brain Tumors Whitney Pope Paul Mischel 3:40-4:05 pm Biomarker Development and Validation from a9:35-9:50 am Q&A Biostatistical Perspective Annette Molinaro9:50-10:10 am Break 4:05-4:25 pm Translating Findings from TCGA into ClinicalImmunotherapy BiomarkersSession Chairs: Maria Castro, Amy Heimberger Jason Huse10:10-10:30 am Vaccine Strategies 4:25-4:45 pm Biomarkers and Antiangiogenic Therapy Duane Mitchell Manish Aghi 4:45-5:05 pm Biomarker Driven Early Clinical Trials and the 10:30-10:50 am Immunotoxins for Glioma Therapeutics: Potential Role in Drug Development Preclinical to Clinical Implementation David Reardon Maria Castro 5:05-5:25 pm Biomarkers and Clinical Care: are we there yet? 10:50-11:10 am Engineered T Cell Approaches Michael Weller Christine Brown Industry Sponsored Symposium:11:10-11:30 am Targeting CTLA-4 Glioma-mediated CNS Cancer Tumor Board: Clinical Investigators Provide Immune Suppression Perspectives on Current Cases from Their Practices Mark Gilbert Not sponsored by The University of Texas MD Anderson Cancer Center11:30-11:50 am Q & A 5:30-7:30 pm 12:00-1:00 pm Boxed Lunches in the Foyer 7:30-10:00 pm Welcome Reception
  4. 4. Quality of Life/Symptom Management Official Opening of MeetingConcurrent Education Day Session Friday, November 16, 2012Thursday, November 15, 2012Supported by the American Brain Tumor Association 6:30-9:00 am Breakfast in the Foyer8:00-8:10 am Introduction Michael Glantz, Chair 7:00-8:00 am Sunrise Sessions8:10-8:55 am Measuring quality of life and recognizing EANO and SNO Joint Session: impairment in neuro-oncology patients From Guidelines To New Trials in Low Grade Tobias Walbert, Martin Klein Gliomas: The American and European Views Riccardo Soffietti, Mark Gilbert, moderators8:55-9:30 am Meeting of two minds: How close is the bench • What is the role of awake surgery? to the bedside? Guy McKhann II, Hugues Duffau Jorg Dietrich • What is the role of chemotherapy? David Schiff, Riccardo Soffietti9:30-10:15 am Quality of life in neuro-oncology: How we started, where we’ve been, and the challenges NF2 Update: Hearing Restoration and that lay ahead Foundations for the Future Victor Levin, William Shapiro Scott Plotkin, moderator • Current Treatment for Neurofibromatosis 2-related10:15-10:30 am Break acoustic neuroma: Observation, Surgery, and Radiation TherapyCutting Edge Therapy to Improve Quality of Life in Frederick BarkerPatients With Primary and Metastatic Brain Tumors • Anti-VEGF drug Therapy for NF2-related vestibular schwan- noma: Endpoints and Results10:30-11:05 am Symptom Management – Scott Plotkin An Instructional Manual, Part I • Restoring Sound Perception to the Deaf Patient: Brainstem Glen Stevens and Cochlear Implants William Slattery11:05-11:30 am Symptom Management - • Molecular Targets and Foundations for Future Trials An Instructional Manual, Part II Jaishri Blakeley Jennie Rexer Energetics and Metabolism11:30-12:00 pm Evidence-based medicine meets quality of life Mariano Viapiano, moderator in neuro-oncology • Molecular sensors of metabolism (AMPK) Edward Shaw Elizabeth Maher12:00-1:00 pm Boxed Lunches in the Foyer • Cytochrome c oxidase: Emerging mitochondrial target to overcoming chemoresistance in gliomas Corinne Griguer • An Evaluation of IDH1 Mutant Metabolic Alterations as a Therapeutic Target in GBM Gregory Riggins Re-engineered T Cells and Bone Marrow Cells Robert Carter, moderator • New Approaches to Cellular Immunotherapy of Glioblastoma Steven Rosenberg • MGMTP140K-mediated chemoprotection in patients with glioblastoma Hans-Peter Kiem • Other targets Robert Carter
  5. 5. Morning Plenary Session Noon- 1:00 pm Boxed Lunches in the Foyer 8:10 am Introduction and Welcome Industry Supported Event E. Antonio Chiocca, Lymphomatous Meningitis Scientific Meeting Program Chair Not supported by The University of Texas MD Anderson Cancer Center Public Service Award: Edward G. Shaw Young Investigator Roundtable Luncheon8:30-11:00 am Plenary Session 1 Pre-registration via SNO website required Top Scoring Abstracts: Basic Science 1:00-3:00 pm Concurrent Session 2A8:30 am AI-21 Spatiotemporal Regulation of GBM Neo-vascularization and Response to Therapy Medical, Neuro- and Radiation Oncology ADULT TRANSLATIONAL RESEARCH WINNER 1:00 pm NO-75 RO4929097 in Combination with Radiotherapy Gelareh Zadeh and Temozolomide for Newly Diagnosed8:45 am SC-04 Know thy enemy: the development of imaging Malignant Glioma (MG): a Pharmacokinetic (PK) models to interrogate the complexity of cancer and Pharmacodynamic (PD) Study stem cells in malignant brain tumors Antonio Omuro ADULT BASIC SCIENCE AWARD CO-WINNER 1:15 pm NO-56 RTOG 0131: Phase II trial of pre-irradiation Justin D. Lathia and concurrent temozolomide in patients with 9:00 am TM-06 Development of pediatric glioma models for newly diagnosed anaplastic oligodendrogliomas BRAF-targeted therapy and mixed anaplastic oligodendrogliomas - PEDIATRIC TRANSLATIONAL AWARD WINNER updated survival and progression free survival Shih-Shan Lang analysis9:15 am PL-02 Molecular characterization of mutated histone Michael A. Vogelbaum H3.3 in pediatric glioblastoma 1:30 pm NO-62 Patterns of Treatment and Survival of GBM PEDIATRIC BASIC SCIENCE AWARD WINNER Patients with Diabetes Mellitus Sebastian Bender Chao Yin9:30 am ET-27 A novel class of small molecules prevent glioma 1:45 pm PA-22 Adult pilocytic astrocytoma: clinical features growth and inhibit HIF binding to transcription and molecular analysis co-factors p300/CBP Benjamin Ellezam 2:00 pm NO-97 Deferred use of bevacizumab for recurrent Erwin G. Van Meir glioblastoma is not associated with diminished 9:45 am SC-41 Cortical GFAP+ astrocytes as a potential cellular efficacy origin of GBM David E. Piccioni ADULT BASIC SCIENCE AWARD CO-WINNER 2:15 pm IT-12 Ex vivo functional analysis, expansion and Ralf S. Schmid adoptive transfer of cytomegalovirus-specific T-cells in patients with glioblastoma multiforme 10:00 am Break David G. Walker 2:30 pm NO-49 Final report for evaluable patients treated on 10:15 am ME-03 New low frequency risk loci in the DM92-035, phase III randomized study of 8q24.21 (CCDC26) region are strongly post-irradiation PCV versus DFMO-PCV, associated with risk of oligodendroglial tumors for anaplastic gliomas (AG) and IDH1/2 mutated astrocytomas Victor A. Levin EPIDEMIOLOGY AWARD WINNER 2:45 pm NO-85 Antibody mediated anti-EGF-R therapy with Robert B. Jenkins nimotuzumab for newly diagnosed10:30 am CB-60 Cytomegalovirus enhances glioblastoma glioblastoma : Correlative analysis of the proliferation via STAT3 activation OSAG-101 phase III study results Richard L. Price Manfred Westphal 1:00-3:00 pm Concurrent Session 2B 10:45 am Abhijit Guha Award Introduction Basic Sciences10:50 am Abhijit Guha Award: James Rutka 1:00 pm AI-03 JAK-1/2 Inhibition Impairs Bone Marrow 11:20 am Keynote Lecture Introduction Derived Cell Recruitment Preventing Low to High Grade Glioma Transformation11:30 am Keynote Lecture: Bert Vogelstein Prajwal Rajappa
  6. 6. 1:15 pm CB-38 Unexpected nuclear sublocalization of the 4:15 pm NC-07 Long-term survivorship in primary tyrosine kinase receptor Tie2 induces glioblastoma: a focus on neurocognition radioresistance of malignant gliomas Katherine B. Peters Candelaria Gomez-Manzano 4:30 pm NC-08 Memantine for the Prevention of Cognitive1:30 pm IR-02 IDO expression suppresses anti-tumor Dysfunction in Patients Receiving Whole-Brain immunity through a T cell-dependent Radiotherapy (WBRT): First Report of RTOG mechanism 0614, a Placebo-Controlled, Double-Blind, Derek A. Wainwright Randomized Trial1:45 pm MP-01 Astrocyte-elevated gene-1 (AEG-1) is Induced Jeffrey S. Wefel by Hypoxia and Glucose Deprivation and Modulates the Glycolytic Phenotype in 4:45 pm NC-11 Magnetic Resonance Imaging associates with Glioblastoma differences in neurocognitive performance for Evan Noch cancer survivors complaining of cognitive2:00 pm PL-16 Blockade of T cell transforming growth deficits following brain irradiation factor-beta signaling mitigates Ann M. Peiffer medulloblastoma progression in transgenic mice 3:15-5:00 pm Concurrent Session 3B Rachelle Levy2:15 pm RB-01 Bromodomain protein Brd4 insulates Molecular Epidemiology, -Omics and Prognostic chromatin from DNA damage signaling and Markers is associated with glioblastoma resistance to radiation 3:15 pm ME-07 Integrated genomic analysis of glioblastoma: an Clark C. Chen update from The Cancer Genome Atlas2:30 pm IR-15 Enhancement of dendritic cell migration to Roel Verhaak vaccine-site draining lymph nodes as a 3:30 pm MP-07 Metabolic modulation of glioblastoma (GBM) means to generate potent anti-tumor immune by depleting Hexokinase II (HK2): potentiating responses the effect of standard therapies Kristen Batich Alenoush Vartanian2:45 pm SC-34 CD133 inheritance depicts asymmetric cell 3:45 pm ME-09 Insight in glioma susceptibility through an division and the generation of tumor analysis of 6p22.3, 12p13.33-12.1, 17q22-23.2 heterogeneity and 18q23 SNP genotypes in familial and Masahiro Hitomi non-familial glioma Yanhong Liu3:00 pm Break 4:00 pm OM-06 Genome Diversity Within a Child’s Medulloblastoma Melanie3:15-5:00 pm Concurrent Session 3A Hayden Gephart 4:15 pm OM-03 IDH/MGMT-driven molecular classification is a Symptom Management, Neuro-cognitive strong predictor for low-grade glioma patient and Quality of Life survivalPatrick Wen, moderator Jean-Louis Boulay 4:30 pm OM-07 Genomic Characterization of Meningiomas 3:15 pm Effects of Chemotherapy Priscilla Brastianos Jorge Dietrich 4:45 pm OM-10 Circulating microvesicles in serum of GBM American Academy of Neurology patients; could they became a new diagnostic invited speaker tool?3:30 pm Effects of Radiotheraphy Marta M. Alonso (TBN), American Academy of Neurology invited speaker 5:00-7:00 pm Management of 1p/19q codeleted3:45 pm SM-27 EANO/SNO Travel Scholarship anaplastic gliomas Award Winner This symposium will discuss the updated results Augmenting quality of life and of the available phase II and III trials, how mastery of informal caregivers of patients should now be managed, what role high-grade glioma patients: A randomized biomarkers have in patient selection, the choice controlled trial of chemotherapy regimen and the design of the Florien Boele, Amsterdam ongoing trials (including CODEL and CATNON).4:00 pm SM-19 Symptoms in Adult Long-Term Survivors of Malignant Brain Tumors Christina M. Amidei 7:00-9 :00pm Poster Viewing Reception
  7. 7. Morning Plenary Session Saturday, November 17, 2012 8:15-9:45 am Pediatric Minisymposium Session 4 6:30-9:00 am Breakfast in the Foyer 8:15 am Introduction7:00-8:00 am Sunrise Sessions 8:30 am Pediatric Glioblastoma: a tale of a histone tail Nada JabadoAsian Society for Neuro-Oncology SessionRyo Nishikawa, moderator 8:50 am Molecular Pathogenesis of Diffuse Intrinsic • Toward understanding the pathogenesis of intracranial germ Pontine Glioma cell tumors Suzanne Baker Koichi Ichimura• Vasculogenic mimicry: Alternative target for glioma treatment 9:10 am Metastatic Medulloblastoma is a Zhong-Ping Chen Bicompartmental Disease Secondary to Clonal • Clinical, molecular correlation and translational study on CNS Selection AT/RT Michael Taylor Tai-Tong Wong• Opportunities and challenges in neuro-oncology practice in 9:30 am Ependymoma India Stefan Pfister Rakesh Jalali• Current PRC reviewed protocols and open clinical trials in KSNO 9:50 am Q&A Ho-Shin Gwak 10:00 am BreakThe CMV and Glioma ConnectionChang-Hyuk Kwon, moderator 10:15am-Noon Plenary Session 5• RNA-pulsed Dendritic Cells Targeting CMV Antigens in GBM Clinical Studies 1 Duane Mitchell• Cytomegalovirus infection accelerates malignant gliomas 10:15 am NO-06 MGMT promoter methylation predicts benefit Chang-Hyuk Kwon from temozolomide versus radiotherapy in • Cytomegalovirus- A Resident and Active Promoter of Glioma malignant astrocytomas in the elderly: the Stem Cells NOA-08 trial Liliana Soroceanu ADULT CLINICAL RESEARCH AWARD CO-WINNERMechanisms of Glioblastoma Immuno-evasion Michael WellerDavid Reardon, moderator 10:30 am NO-64 Clinical course and progression free survival of adult and pedriatic ependymoma: a working • Gordon Freeman model• Andrew Parsa Elizabeth Vera-Bolanos• STAT3 as a molecular hub of glioma-mediated immune sup- 10:45 am OT-03 Phase III trial of bevacizumab added to pression and tumorigenesis standard radiotherapy and temozolomide Amy Heimberger• Peter Fecci for newly-diagnosed glioblastoma: mature progression-free survival and preliminary Pituitary Tumors: Biology and Treatment overall survival results in AVAglioManmeet Ahluwalia, moderator ADULT CLINICAL RESEARCH AWARD CO-WINNER• Pituitary adenoma biology and genetics Olivier Chinot Russell Lonser 11:00 am MR-03 Long term follow up of EORTC 26951, a• Surgical Management of Pituitary Tumors randomized trial on adjuvant PCV Edward Laws chemotherapy in anaplastic oligodendroglial • Radiosurgery for Pituitary Tumors tumors. A report of the EORTC BTG Douglas Kondziolka Martin J. van den Bent
  8. 8. 11:15 am RT-09 To compare the treatment outcomes of two 2:45 pm CB-53 An in vivo loss of function screen for genes different target volume delineation guidelines involved in EGFRvIII-independent glioma growth (RTOG vs M.D. Anderson) in glioblastoma Tiffany E. Taylor multiforme patients: A prospective randomized study 1:00-3:00 pm Concurrent Session 6B Narendra Kumar Epidemiology, Pathology and Radiology11:30 am Introduction to Victor Levin Lecture 1:00 pm PA-09 Histological predictors of outcome in11:40 am Victor Levin Lecture ependymoma are dependent on tumor location Gregory Cairncross in the central nervous system Robert Jenkins Aditya Raghunathan 1:15 pm PA-21 Anti-angiogenic therapy increases tumorNoon Boxed Lunches in the Foyer associated macrophages (TAMs) in recurrent glioblastoma (GBM) patients SNO Business Meeting Christine Lu-Emerson 1:30 pm PA-08 BRAF duplications and MAPK pathway activation are frequent in gliomas of the optic Afternoon Concurrent Sessions nerve proper Fausto J. Rodriguez1:00-3:00 pm Concurrent Session 6A 1:45 pm PA-18 Patterns of repressive histone 3 lysine 9 trimethylation (H3K9me3) in gliomas with and without isocitrate dehydrogenase 1 R132H Cell Biology and Signaling mutation. Sriram Venneti1:00 pm CB-32 Detection of “oncometabolite” 2:00 pm RA-17 Imaging-genomic Necrosis Mapping Reveals 2-hydroxyglutarate by magnetic resonance Gender-specific Survival and Molecular analysis as a biomarker of IDH1/2 mutations in Determinants in GBM glioma Rivka R. Colen Erwin G. Van Meir 2:15 pm EP-12 Gender and Racial Risk Factors for Childhood 1:15 pm CB-35 Ectopic overexpression of miR145 compromises Brain Tumors Cynthia J. Campen the invasive ability of malignant gliomas by 2:30 pm OM-23 Prognostic or predictive value of MGMT modulating NEDD9 promoter methylation in malignant gliomas Maria Carmela Speranza depends on IDH1 mutations1:30 pm TM-12 The potential male-specific oncogenic function Wolfgang Wick of Cdca7l in astrocytoma 2:45 pm RA-05 EANO/SNO Travel Scholarship Min-Hyung Lee Award Winner1:45 pm SC-15 MSH6 mutations arise in malignant glioma both Signal intensity in preoperative prior to and following chemoradiotherapy and diffusion-weighted imaging correlates with survival times in patients with single contribute to temozolomide resistance brain metastasis independently of MGMT promoter Anna Sophie Berghoff, Vienna methylation Stephanie A. Nguyen 3:00-3:15 pm Break2:00 pm SC-27 Identification of novel therapeutic targets through an integrated in vitro and in vivo whole 3:15-5:00 pm Concurrent Session 7A genome shRNA screen in glioma stem cells Simone P. Niclou Angiogenesis and Invasion2:15 pm SC-03 Genome-wide transcriptome analysis defines two mutually-exclusive glioma stem cell 3:15 pm AI-09 Hypoxia Upregulates MiR-451 Expression in subtypes with distinctive clinical features Gliomas David Zagzag Ping Mao 3:30 pm CB-57 Phosphorylation of Dock180Y722 by Src Family 2:30 pm CB-48 Notch Ligands, Lateral Inhibition and Stem-like Kinases Mediates EGFRvIII-Driven Glioblastoma Glioblastoma Cells Tumorigenesis Kah Jing Lim Shiyuan Cheng
  9. 9. 3:45 pm CB-16 Stress-regulated expression of miR-451 controls proliferation/migration dichotomy of Sunday, November 18, 2012 glioblastoma in vitro and in vivo impacting radio- and chemo-response Daisuke Ogawa 6:30-9:00 am Breakfast in the Foyer4:00 pm SC-16 Platelet-derived growth factor receptors differentially inform intertumoral and 7:00-8:00 am Sunrise Sessions intratumoral heterogeneity Youngmi Kim Oncolytic Viruses: Clinical Trials Update4:15 pm CB-03 Fibulin-3 promotes glioma growth and Evanthia Galanis, moderator resistance through a novel paracrine regulation of Notch signaling • Oncolytic measles strains in GBM treatment: an update Mariano S. Viapiano Evanthia Galanis4:30 pm RB-14 Invasion and proliferation kinetics predict IDH-1 • Delta-24-RGD adenovirus: ongoing hopes and challenges mutation in contrast-enhancing gliomas Juan Fueyo Anne L. Baldock • Toca5114:45 pm AI-24 VEGF Blockade results in Epithelial Nori Kasahara Mesenchymal transition in Glioblastoma • Clinical Trials of HSV-1 for Glioma Viviane Tabar Jim Markert3:15-5:00 pm Concurrent Session 7B The Radiobiology of CNS Tumors Gelareh Zadeh, moderatorSurgery and Immunology • Targeting vasculogenesis: A new paradigm for the treatment3:15 pm IR-18 Adoptive transfer immunotherapy targeting of brain tumors NY-ESO-1 for treatment of glioblastoma Martin Brown Richard G. Everson • Radiation Biology Essentials3:30 pm IR-07 S100B promotes glioma growth through Richard Hill chemoattraction of myeloid-derived • Molecular Determinants of Radiation Response and Toxicity macrophages Arnab Chakravrarti Leying Zhang • Microenvironmental influences on the radiation response of3:45 pm IR-17 Tumor-infiltrating lymphocytes in glioblastoma brain are associated with NF1, TP53, and RB1 John Fike mutations and the mesenchymal transcriptional subtype The Biology of Brain Metastases William C. Rutledge Peter Forsyth, moderator4:00 pm NS-03 Never say never: Risk factors for, and consequences of hospital acquired never • Rakesh Jain • Deeper insights into the crucial steps of brain metastasis events in neuro-oncologic surgery Frank Winkler Brad E. Zacharia • Molecular and Preclinical Advances in Brain Metastasis of4:15 pm NS-15 Complications and outcomes in recurrent Breast Cancer glioma surgery Brunilde Gril Ian F. Parney4:30 pm IT-23 Vemurafenib and radiation therapy in MicroRNA Biology in CNS Tumors melanoma brain metastasis Sean Lawler, moderator Ashwatha Narayana4:45 pm IT-13 WT1 peptide vaccination for newly diagnosed • Novel anti-apoptotic onco-miRs in glioblastoma glioblastomas; phase I clinical trial of stem-like cells combination with temozolomide Benjamin Purow Naoya Hashimoto • Mark Johnson • Jakub Godlewski5:00-7:00 pm Poster Viewing Reception • Peripheral micro RNA biomarkers for primary and metastatic brain tumors7:15-10:00 pm Banquet Anne Krichevsky
  10. 10. 7:00-8:00 am SNO Highlights Session 10:30 am IT-20 Dendritic Cell Vaccines Targeting Human (By invitation only) Cytomegalovirus in Glioblastoma Reveal Lymph Node Homing as Major Axis for Clinical InterventionMorning Plenary Session Duane A. Mitchell8:15-10:45 am Plenary Session 8 10:45-1145 am RANO Session Clinical Studies 2 10:45 am Welcome8:15 am PC-05 Final Report of Outcome of the CCG-99703 10:50 am Validation of the RANO recommendations Children’s Oncology Group Study for Children Summary of Wick and Gerstner efforts Less Than 3 Years of Age Newly-Diagnosed with Malignant 11:00 am Ongoing efforts PEDIATRIC CLINICAL RESEARCH RAPNO, Mets, Meningioma AWARD WINNER Jonathan Finlay 11:20 am Discussion of use of TTP versus 6 mo PFS as 8:30 am NS-13 Complete, but not partial resection is important endpoints for recurrent GBM studies in the era of radiotherapy, concomitant and Summary of Chang and Wu talks adjuvant temozolomide for glioblastoma patients 11:30 am Opportunities for future efforts Jörg-Christian Tonn Discussion of process8:45 am IT-01 Peptide vaccine therapy for childhood gliomas: Updated Results of a Pilot Study 11:40 am Open discussion Ian F. Pollack9:00 am EP-09 An exploratory gene-environment-wide 12:00 pm Adjourn interaction study (GEWIS) of childhood medulloblastoma survival Michael E. Scheurer 12:00-2:30 pm Career Development and Networking Session 9:15 am MR-02 A revised RTOG Recursive Partitioning Analysis Lunch provided. Preregistration via SNO (RPA) model for glioblastoma based upon website required. multi-platform biomarker profiles Arnab Charkravarti 9:30 am NC-04 Hippocampus as a dose constraint model to Join SNO! preserve neurocognition in young patients with low-grade brain tumors treated with Membership is available at 3 levels: Full, Associate, and focal stereotactic conformal radiotherapy: data Trainee. Full membership requires doctorate-level degree. from a prospective clinical trial Associate memberships are available for those without QUALITY OF LIFE AWARD WINNER doctorate-level degrees, whose work involves neuro-oncol- Rakesh Jalali ogy-related practice or research. Trainee memberships are9:45 am NO-82 Bevacizumab given with temozolomide and available to those in scientific or clinical training who do radiation therapy (RT) in newly diagnosed not hold faculty appointments. patients with glioblastoma multiforme (GBM) reduces the chance of early radiologic Full or Associate memberships are $200.00 per year; progression Trainee memberships are $75 per year. Lloyd M. Alderson Members receive the following benefits:10:00 am Break • Twelve monthly issues of Neuro-Oncology • Discount to the annual SNO Scientific Meeting10:15 am OM-21 Intrinsic molecular subtypes of glioma are and Education Day prognostic and predict benefit from adjuvant • Regular e-blasts and neuro-oncology news PCV chemotherapy in anaplastic • Access to members-only section of the SNO website oligodendroglial brain tumors. A report from EORTC study 26951 Visit: to join. Pim French
  11. 11. Society for Neuro-Oncology4617 Birch Street, Bellaire, TX 77401-5509 Tel: 713-349-0952 E-Fax: 832-201-8129